RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. today announced that the company will present at the 3rd Annual Dermatology Summit. The conference will take place on January 10, 2016 from 9:30 am to 7:00 pm PST at the Palace Hotel in San Francisco, CA.
The Viamet presentation will highlight VT-1161, a novel, highly potent and selective, oral inhibitor of fungal CYP51, a well-validated antifungal target. During the presentation, Amir Tavakkol, Ph.D., Viamet Chief Development Officer, will provide an update on the company’s ongoing RENOVATE Phase 2b clinical trial of VT-1161 for the oral treatment of toenail onychomycosis.
